KR100726699B1 - 부프레노르핀을 함유하는 진통 조성물 - Google Patents

부프레노르핀을 함유하는 진통 조성물 Download PDF

Info

Publication number
KR100726699B1
KR100726699B1 KR1020027006375A KR20027006375A KR100726699B1 KR 100726699 B1 KR100726699 B1 KR 100726699B1 KR 1020027006375 A KR1020027006375 A KR 1020027006375A KR 20027006375 A KR20027006375 A KR 20027006375A KR 100726699 B1 KR100726699 B1 KR 100726699B1
Authority
KR
South Korea
Prior art keywords
buprenorphine
naloxone
naltrexone
nalmefene
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027006375A
Other languages
English (en)
Korean (ko)
Other versions
KR20020058022A (ko
Inventor
쉐플레오크리스토퍼부른
맥커맥케이트
버레이니콜라스칼버트
Original Assignee
레킷트 벵키저 헬스케어(유케이)리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927359.1A external-priority patent/GB9927359D0/en
Application filed by 레킷트 벵키저 헬스케어(유케이)리미티드 filed Critical 레킷트 벵키저 헬스케어(유케이)리미티드
Publication of KR20020058022A publication Critical patent/KR20020058022A/ko
Application granted granted Critical
Publication of KR100726699B1 publication Critical patent/KR100726699B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020027006375A 1999-11-19 2000-11-17 부프레노르핀을 함유하는 진통 조성물 Expired - Fee Related KR100726699B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9927359.1A GB9927359D0 (en) 1999-11-19 1999-11-19 Improvements in or relating to organic compositions
GB9927359.1 1999-11-19
US17620800P 2000-01-14 2000-01-14
US60/176,208 2000-01-14

Publications (2)

Publication Number Publication Date
KR20020058022A KR20020058022A (ko) 2002-07-12
KR100726699B1 true KR100726699B1 (ko) 2007-06-13

Family

ID=26316086

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027006375A Expired - Fee Related KR100726699B1 (ko) 1999-11-19 2000-11-17 부프레노르핀을 함유하는 진통 조성물

Country Status (30)

Country Link
US (4) US6995169B2 (OSRAM)
EP (1) EP1242087B1 (OSRAM)
JP (1) JP4745576B2 (OSRAM)
KR (1) KR100726699B1 (OSRAM)
CN (1) CN100431543C (OSRAM)
AR (1) AR031682A1 (OSRAM)
AT (1) ATE262335T1 (OSRAM)
AU (1) AU777259B2 (OSRAM)
BR (1) BR0015580A (OSRAM)
CA (1) CA2392013C (OSRAM)
CO (1) CO5261517A1 (OSRAM)
CZ (1) CZ303160B6 (OSRAM)
DE (1) DE60009346T2 (OSRAM)
DK (1) DK1242087T3 (OSRAM)
ES (1) ES2214334T3 (OSRAM)
GB (1) GB2356348B (OSRAM)
HU (1) HU229565B1 (OSRAM)
IL (2) IL149580A0 (OSRAM)
MX (1) MXPA02004978A (OSRAM)
NO (1) NO321965B1 (OSRAM)
NZ (1) NZ519023A (OSRAM)
PL (1) PL199727B1 (OSRAM)
PT (1) PT1242087E (OSRAM)
RO (1) RO121174B1 (OSRAM)
RU (1) RU2255737C2 (OSRAM)
SI (1) SI21025B (OSRAM)
SK (1) SK286888B6 (OSRAM)
TR (1) TR200400653T4 (OSRAM)
TW (1) TW550070B (OSRAM)
WO (1) WO2001035942A2 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
CA2569958C (en) 2004-06-12 2016-03-22 Jane C. Hirsh Abuse-deterrent drug formulations
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
US8093261B2 (en) 2006-10-24 2012-01-10 The Johns Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
MX343867B (es) * 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447015A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447014A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
MX2010002409A (es) * 2007-09-03 2010-05-19 Nanotherapeutics Inc Composiciones y metodos para la distribucion de farmacos escasamente solubles.
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
CN104873455B (zh) 2010-12-22 2023-09-12 普渡制药公司 包覆的抗篡改控制释放剂型
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EP2915525B1 (en) 2011-09-19 2021-08-11 Orexo AB Sublingual abuse-resistant tablets comprising buprenorphine and naloxone
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CN104955483A (zh) 2013-01-30 2015-09-30 法莫斯医疗公司 用低剂量药剂治疗抑郁症和其它疾病
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
SG10201809280PA (en) * 2014-04-22 2018-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
WO2021158957A1 (en) * 2020-02-05 2021-08-12 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002251A1 (en) * 1994-07-19 1996-02-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8430109D0 (en) 1984-11-29 1985-01-09 Gkn Technology Ltd Securing components
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
RU2077326C1 (ru) * 1992-12-29 1997-04-20 Ярыгин Владимир Никитич Препарат для анальгезии
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
JP2004501094A (ja) * 2000-05-05 2004-01-15 ペイン・セラピューティクス・インコーポレイテッド オピオイドアゴニストの効力を増強するか、またはオピオイドアゴニストの有害な副作用を減弱するための新規な組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002251A1 (en) * 1994-07-19 1996-02-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists

Also Published As

Publication number Publication date
CN100431543C (zh) 2008-11-12
PL199727B1 (pl) 2008-10-31
EP1242087B1 (en) 2004-03-24
RU2255737C2 (ru) 2005-07-10
ATE262335T1 (de) 2004-04-15
WO2001035942A9 (en) 2002-11-28
WO2001035942A2 (en) 2001-05-25
JP2003514013A (ja) 2003-04-15
US20060069113A1 (en) 2006-03-30
KR20020058022A (ko) 2002-07-12
BR0015580A (pt) 2002-07-09
IL149580A (en) 2007-05-15
GB2356348A (en) 2001-05-23
ES2214334T3 (es) 2004-09-16
US20030004178A1 (en) 2003-01-02
SI21025A (sl) 2003-04-30
SI21025B (sl) 2008-04-30
CN1413110A (zh) 2003-04-23
RU2002116361A (ru) 2004-01-27
NZ519023A (en) 2004-11-26
DK1242087T3 (da) 2004-07-19
NO20022330L (no) 2002-07-04
JP4745576B2 (ja) 2011-08-10
RO121174B1 (ro) 2007-01-30
US6995169B2 (en) 2006-02-07
SK8762002A3 (en) 2002-12-03
EP1242087A2 (en) 2002-09-25
US20060058333A1 (en) 2006-03-16
HU229565B1 (hu) 2014-02-28
DE60009346T2 (de) 2005-02-10
HUP0203588A2 (hu) 2003-03-28
MXPA02004978A (es) 2003-01-28
HUP0203588A3 (en) 2005-01-28
US20060058332A1 (en) 2006-03-16
NO20022330D0 (no) 2002-05-15
CZ303160B6 (cs) 2012-05-09
AR031682A1 (es) 2003-10-01
DE60009346D1 (de) 2004-04-29
WO2001035942A3 (en) 2002-06-13
GB2356348B (en) 2002-02-06
AU777259B2 (en) 2004-10-07
PT1242087E (pt) 2004-06-30
CA2392013A1 (en) 2001-05-25
NO321965B1 (no) 2006-07-31
SK286888B6 (sk) 2009-07-06
HK1055389A1 (zh) 2004-01-09
IL149580A0 (en) 2002-11-10
PL355330A1 (en) 2004-04-19
TW550070B (en) 2003-09-01
CA2392013C (en) 2009-08-11
CO5261517A1 (es) 2003-03-31
TR200400653T4 (tr) 2004-04-21
AU1529701A (en) 2001-05-30
US7402591B2 (en) 2008-07-22
GB0028088D0 (en) 2001-01-03

Similar Documents

Publication Publication Date Title
KR100726699B1 (ko) 부프레노르핀을 함유하는 진통 조성물
DK163711B (da) Analgetisk praeparat paa enhedsdosisform
KR20090115863A (ko) 부프레노르핀 및 날록손을 함유하는 개량된 약용 조성물
EP0236477B1 (en) Use of 6-methylene-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphine
ZA200203902B (en) Analgesix compositions containing buprenorphine.
HK1055389B (en) Analgesic compositions containing buprenorphine
Muir et al. Psychological stress and oxytocin treatment during pregnancy affect central norepinephrine, dopamine and serotonin in lactating rats
HK1176006A (en) Improved medicinal composition comprising buprenorphine and naltrexone
HK1139870A (en) Improved medicinal compositions comprising buprenorphine and naloxone

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20130523

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20140526

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20150522

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160605

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160605